BPC-157: What the Research Actually Shows About Gut Healing and Tissue Repair

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a sequence found in human gastric juice, and it has been one of the most widely discussed peptides in both research literature and online communities. But what does the published evidence actually support? This review, compiled by the Peptide Register as part of its independent research reference mission, examines the data with full transparency about evidence quality and limitations.

For readers unfamiliar with peptide classification and terminology, our guide on how peptides differ from proteins, hormones, and small molecules provides useful background.

What Is BPC-157 and Where Does It Come From?

BPC-157 is a partial sequence of a protein called BPC, which is naturally present in human gastric juice. The synthetic 15-amino-acid fragment was first isolated and studied by researchers at the University of Zagreb in the early 1990s. BPC-157 is a synthetic pentadecapeptide that does not occur in nature in its isolated form. It is stable in gastric acid, which is unusual for peptides and has driven interest in oral bioavailability. Researchers have studied it primarily through injection (intraperitoneal and subcutaneous) and, to a lesser extent, through oral administration in animal models.

Animal Study Evidence: Gastrointestinal Protection

The majority of published BPC-157 research has been conducted in rodent models. In these studies, BPC-157 has shown protective effects on gastric mucosa in multiple animal models of ulcer formation. Specifically, rat studies have reported accelerated healing of gastric ulcers, reduced mucosal damage from ethanol and NSAID administration, and protective effects in models of inflammatory bowel disease. BPC-157 has been studied in rat models of inflammatory bowel disease, where it reduced lesion severity and inflammatory markers. One proposed mechanism involves upregulation of growth factor expression, including EGF and VEGF receptor signalling, along with nitric oxide system modulation.

Studies from the University of Zagreb group have also reported that BPC-157 demonstrated cytoprotective effects in rat models of short bowel syndrome and intestinal anastomosis healing. These findings are notable but carry significant caveats: most come from a single research group, sample sizes are typically small (8 to 12 animals per group), and independent replication by other laboratories remains limited.

Animal Study Evidence: Tendon, Ligament, and Musculoskeletal Repair

Beyond the gut, BPC-157 has been investigated in animal models of connective tissue injury. BPC-157 accelerated Achilles tendon healing in a transected rat tendon model, with treated animals showing increased collagen organisation and biomechanical strength. Rat studies have also reported positive outcomes in models of muscle crush injury, ligament transection, and bone fracture healing. Some researchers have reported that BPC-157 promoted angiogenesis at wound sites in animal studies, potentially through VEGF-mediated pathways.

Again, the vast majority of this work originates from the same Croatian research group. While the consistency of findings across multiple tissue types is noteworthy, the lack of independent replication is a meaningful limitation that researchers should weigh when interpreting these results. Our guide on how to read peptide research covers how to evaluate single-group findings and animal-to-human translation.

Human Clinical Evidence: Limited and Preliminary

As of 2025, no large-scale randomised controlled trials of BPC-157 have been published in peer-reviewed journals. No large-scale human randomised controlled trials of BPC-157 have been published as of 2025. A small number of early-phase studies and case series have appeared, but these are insufficient to draw conclusions about efficacy or safety in humans. The contrast between extensive animal data and minimal human clinical data is one of the defining features of the BPC-157 evidence base.

BPC-157 is not approved for human therapeutic use by the FDA, TGA, or EMA. In the United States, the FDA placed BPC-157 on its Category 2 list of substances that cannot be used in compounding under current guidance, citing insufficient safety data. In Australia, BPC-157 is not listed on the Australian Register of Therapeutic Goods and is classified as a prescription-only substance under TGA scheduling. Our overview of peptide regulation across jurisdictions provides further regulatory context.

Evidence Gaps and What They Mean

BPC-157 has over 100 published animal studies spanning gastrointestinal, musculoskeletal, and neurological models. However, BPC-157's published evidence base consists almost entirely of animal studies, with most originating from a single research group in Croatia. Long-term safety data in humans do not exist in the published literature. Potential interactions with other compounds, effects on human tumour biology, and pharmacokinetics in humans remain unstudied or underreported.

The peptide's mechanism of action, while explored in animal tissue, is not fully characterised. Proposed pathways include nitric oxide modulation, growth factor upregulation, and interaction with the dopamine system, but these remain hypotheses supported by rodent data rather than confirmed human mechanisms.

Researchers and clinicians reviewing BPC-157 should note that promising animal findings do not predict human efficacy or safety. The Peptide Register catalogues BPC-157 alongside other peptides in its research database, providing structured profiles that distinguish between animal and human evidence levels. For further reading on the regulatory trajectory of peptides moving from research to clinical application, see our post on the future of peptide therapy.